Shingles vaccine might help slow down the progression of dementia in current patients

Shingles Vaccine May Slow Dementia Progression

A recent study conducted by Stanford University suggests that the shingles vaccine could potentially slow down the progression of dementia. This research builds on earlier findings which indicated that older individuals who received the vaccine had a 20% lower likelihood of developing dementia over seven years compared to those who were not vaccinated.

Dr. Pascal Geldsetzer, the lead author of the study, expressed, “For the first time, we have evidence of a likely causal relationship between shingles vaccination and the prevention and treatment of dementia.”

The research team analyzed public health data from Wales, where access to the shingles vaccine (Zostavax) was primarily determined by birthdate. This created two groups of older adults with similar demographics, allowing for a more accurate comparison of dementia rates between vaccinated and unvaccinated individuals.

The initial analysis revealed that the vaccine’s benefits spanned from early cognitive decline indications to late-stage dementia signs. Over a period of nine years, vaccinated individuals were less frequently diagnosed with mild cognitive impairment.

Furthermore, people who were vaccinated after their dementia diagnosis had a significantly lower mortality rate from dementia over the following nine years, indicating that the vaccine might help slow disease progression. In fact, nearly half of older adults with dementia at the start of the vaccination program ultimately succumbed to the condition, compared to just 30% of those who received the vaccine.

Dr. Geldsetzer noted, “A growing body of research shows that viruses that preferentially target the nervous system may play a role in dementia development.” This includes the varicella virus, which can reactivate as shingles in older age, potentially causing inflammation in or around the brain. As inflammation is linked to dementia risk, preventing these viral flare-ups might also help reduce that risk.

However, the researchers acknowledged a significant limitation in their study. The health behaviors of vaccinated participants may differ from those who did not receive the vaccine, and such details aren’t available in electronic medical records. For instance, they lack information on dietary habits or levels of physical activity.

Dr. Geldsetzer emphasized that if the shingles vaccine does indeed slow or prevent dementia as indicated by this study, it would represent a crucial advancement for clinical medicine and public health.